Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday


As the trading week kicks off, investors are closely monitoring the pre-market stock movers to gauge market sentiment and identify potential investment opportunities. In this article, we will delve into the biggest gainers and losers in the pre-market session on Monday, November 6th, 2023. From soaring stocks to plummeting shares, we will explore the factors driving these movements and provide insights into the latest stock market news.

Top Gainers

Carbon Revolution (NASDAQ:CREV)

Carbon Revolution (NASDAQ:CREV) stock is experiencing an astronomical surge, skyrocketing more than 286% following its recent public debut on Friday. This remarkable rally has also propelled Carbon Revolution (NASDAQ:CREVW) warrants up by over 75%. The strong market response to Carbon Revolution’s public offering reflects investor enthusiasm for the company’s innovative carbon fiber wheel technology.

Super League Enterprise (NASDAQ:SLE)

Super League Enterprise (NASDAQ:SLE) shares are soaring by more than 32% in the pre-market session, despite the absence of any apparent news. This unexpected surge has captured investors’ attention and suggests that there may be underlying factors driving the stock’s upward momentum.

OrganiGram (NASDAQ:OGI)

OrganiGram (NASDAQ:OGI) stock is surging over 29% after securing a substantial C$125 million investment. This significant infusion of capital signals confidence in OrganiGram’s growth prospects within the cannabis industry. The funds are expected to support the company’s expansion plans and drive innovation in its product offerings.

RiceBran Tech (NASDAQ:RIBT)

Shares of RiceBran Tech (NASDAQ:RIBT) are witnessing a remarkable increase of more than 21% in the pre-market session. While the exact catalyst for this surge is unclear, investors are likely responding positively to the company’s recent developments, such as partnerships, product launches, or industry-related news.

Posco (NYSE:PKX)

Posco (NYSE:PKX) stock is gaining over 18% after the company announced a dividend. Dividends are a key factor for investors seeking stable returns from their investments, and Posco’s decision to distribute dividends has likely attracted positive attention from the market.

Sensei Biotherapeutics (NASDAQ:SNSE)

Sensei Biotherapeutics (NASDAQ:SNSE) shares are climbing more than 18% following an unsolicited bid for its stock. The bid indicates potential interest and confidence in Sensei Biotherapeutics’ business and growth prospects. Investors are eagerly observing the outcome of this bid and its potential impact on the company’s stock performance.

Direxion Daily South Korea Bull 3X Shares (NYSEARCA:KORU)

Direxion Daily South Korea Bull 3X Shares (NYSEARCA:KORU) stock is receiving a significant boost of over 18% in the pre-market session. While the exact catalyst for this surge remains unknown, it may be attributed to favorable developments in the South Korean market or positive sentiment towards the region’s economy.


ESGL (NASDAQ:ESGL) shares are jumping more than 18%, even in the absence of any obvious news. This surge suggests that investors may be responding to technical indicators, market trends, or other factors that have influenced buying interest in ESGL stock.

Kiora Pharmaceuticals (NASDAQ:KPRX)

Kiora Pharmaceuticals (NASDAQ:KPRX) stock is up over 17%, likely driven by positive clinical trial results. The successful outcome of clinical trials can significantly impact the valuation and market sentiment towards pharmaceutical companies, leading to increased investor interest.


NexImmune (NASDAQ:NEXI) stock is plummeting more than 21% as the company continues its wind-down plans. The decline reflects investor concerns about the company’s future prospects and the potential impact of its wind-down strategy on shareholder value.

RiskOn International (NASDAQ:ROI)

Shares of RiskOn International (NASDAQ:ROI) are diving close to 17% following a delisting notice. Delisting notices can have a severe impact on stock prices, as they indicate potential challenges or issues faced by the company, casting doubt on its future performance.

Top Losers

Benson Hill (NYSE:BHIL)

Benson Hill (NYSE:BHIL) stock is tumbling over 16% in the pre-market session. While the specific reasons for this decline are unclear, investors may be reacting to factors such as disappointing financial results, negative industry trends, or other adverse market developments.

Kazia Therapeutics (NASDAQ:KZIA)

Kazia Therapeutics (NASDAQ:KZIA) shares are taking a beating of more than 13% this morning. The decline may be attributed to factors such as unfavorable clinical trial results, regulatory setbacks, or broader challenges within the biotech sector.


Affimed (NASDAQ:AFMD) stock is dropping over 13% after presenting preclinical data. The market’s response to preclinical data can vary significantly based on factors such as the potential of the drug candidate, its perceived competitiveness in the market, or any concerns raised during the presentation.

Sigma Additive Solutions (NASDAQ:SASI)

Shares of Sigma Additive Solutions (NASDAQ:SASI) are falling almost 13% without any apparent news. This decline may be influenced by general market sentiment, profit-taking by investors, or other factors unrelated to the company’s specific operations or performance.

Mangoceuticals (NASDAQ:MGRX)

Mangoceuticals (NASDAQ:MGRX) stock is sliding over 11% in the pre-market session. While the exact catalyst for this decline is uncertain, it may be attributed to factors such as negative industry trends, concerns about the company’s financial health, or broader market sentiment.

Brainstorm Cell (NASDAQ:BCLI)

Brainstorm Cell (NASDAQ:BCLI) shares are decreasing nearly 11% after receiving a delisting notice. Delisting notices can have a significant impact on stock prices as they signal potential challenges or issues faced by the company, which can erode investor confidence.

Kodiak Sciences (NASDAQ:KOD)

Kodiak Sciences (NASDAQ:KOD) stock is slipping over 10% following the release of Phase 3 clinical trial data. The market’s response to clinical trial data can vary depending on factors such as the efficacy of the treatment, potential side effects, or the competitive landscape within the disease area being targeted.


Atreca (NASDAQ:BCEL) shares close out our pre-market stock movers, down more than 10% on Monday. The reasons for this decline are unclear, but it may be influenced by broader market sentiment, company-specific factors, or other industry-related developments.


In conclusion, the pre-market session on Monday, November 6th, 2023, witnessed significant movements in various stocks. While some companies experienced remarkable gains driven by factors such as successful public offerings, strategic investments, or positive clinical trial results, others faced declines due to wind-down plans, delisting notices, or disappointing data presentations. These pre-market movements provide valuable insights for investors, highlighting the importance of staying informed and monitoring market trends to make informed investment decisions.

Financial Disclaimer

The information provided in this stock report is for informational purposes only and is not intended for trading purposes. The report does not constitute investment advice, nor is it an offer or solicitation of an offer to buy or sell any securities or other financial instruments. All information, including stock prices, market data, company fundamentals, and analyst ratings, is provided on an “as is” basis for informational purposes only, and is not intended for trading purposes or advice.

Past performance of the stocks mentioned in this report is not indicative of future results. Investing in stocks involves risks, including the loss of principal. Investors should consider their investment objectives and risks carefully before investing. The content of this report is not intended to provide legal, tax, or financial planning advice, and investors are advised to consult with a qualified professional for this type of advice.

All investments involve risks, including the possible loss of capital. The author and publisher of this report are not liable for any actions taken as a result of this report. It is recommended that readers conduct their own independent analysis or consult a qualified financial advisor before making any investment decisions.

You may also like...